Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology
/PRNewswire/ -- Lucius Partners, LLC today reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study...